Market Cap 372.24M
Revenue (ttm) 216.11M
Net Income (ttm) -220.47M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -102.02%
Debt to Equity Ratio 0.00
Volume 884,100
Avg Vol 1,405,410
Day's Range N/A - N/A
Shares Out 60.14M
Stochastic %K 35%
Beta 0.65
Analysts Strong Sell
Price Target $14.90

Company Profile

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for prev...

Industry: Biotechnology
Sector: Healthcare
Phone: 202 734 3400
Address:
2200 Pennsylvania Avenue NW, Suite 300E, Washington, United States
Wolfietrader
Wolfietrader May. 25 at 8:08 PM
$VNDA I just saw their silly cartoon commercial during the Paris Open. What a joke
0 · Reply
RayaK16
RayaK16 May. 23 at 11:34 PM
0 · Reply
elmono
elmono May. 23 at 7:30 AM
$VNDA their biggest mistake is that they are overspending. Cut cost by 50% and this is going somewhere….otherwise next offering in Q4
0 · Reply
BullMaven
BullMaven May. 22 at 3:12 PM
$VNDA adding 500
0 · Reply
TomMac64
TomMac64 May. 22 at 1:56 PM
$VNDA My favorite Company , stock , play , whatever ; this is gonna be $10 …..
0 · Reply
Cmhatwell
Cmhatwell May. 22 at 12:52 PM
$VNDA merger monday, oh wait a minute.
1 · Reply
Investor203
Investor203 May. 22 at 11:49 AM
$AKTX any hope for $VNDA?
2 · Reply
jacckkmm
jacckkmm May. 21 at 11:04 AM
$VNDA is a player here!The Charcot–Marie–Tooth disease market is poised for steady growth, driven by increasing disease awareness and improved diagnostic capabilities. Advancements in genetic testing are enabling earlier and more accurate diagnosis, expanding the identifiable patient pool. Additionally, the expected launch of emerging therapies such as IFB-088 (InFlectis BioSciences), Govorestat (Applied Therapeutics), Ignaseclant (NMD670) (NMD Pharma), ABS-0871 (Actio Biosciences), VCA-894A (Vanda Pharmaceuticals), EDK060 (Novartis), AGT-100216 (Augustine Therapeutics), and others will further boost the market growth forward.
1 · Reply
veryboredXYZ
veryboredXYZ May. 21 at 1:36 AM
$VNDA time to turn this around. Enough bleeding
0 · Reply
BioRich
BioRich May. 20 at 11:14 PM
$SLS The more y'all play childish games, the more I feel it's easier to respond broadly than specifically. Here's another one of your distraught RH's. @Jesse1011 THOUSANDS of posts, and you hand select these? Interesting. $GUTS doubled after I picked it. $SLS 8x'd after i picked it. $CAPR multipled and the list goes on. $GPCR, you point out that i asked if something leaked. That's it. And someone explained the upward movement. It's often included in BO discussions, which I still believe it gets. $VNDA is great and have made lots on them. Added for earnings and the did what appeared to be an unnecessary offering. Still massively green on it and expect a natural rebound. ANVS... you saw what it did after my post, right? You know, the respinse that was exsctly like i suggested. So keep highlighting my excellence. And it'll be beautiful when you look at my posts exposing $SLS in the future. Because lets be real, that's the only reason you're acting out.
9 · Reply
Latest News on VNDA
Vanda Pharmaceuticals Slides: Corporate presentation

May 18, 2026, 7:00 AM EDT - 7 days ago

Vanda Pharmaceuticals Slides: Corporate presentation


Vanda Pharmaceuticals Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 19 days ago

Vanda Pharmaceuticals Earnings Call Transcript: Q1 2026


Vanda Pharmaceuticals Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 19 days ago

Vanda Pharmaceuticals Earnings release: Q1 2026


Vanda Pharmaceuticals Quarterly report: Q1 2026

May 6, 2026, 4:30 PM EDT - 19 days ago

Vanda Pharmaceuticals Quarterly report: Q1 2026


Vanda Pharmaceuticals Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 4 weeks ago

Vanda Pharmaceuticals Proxy statement: Proxy filing


Vanda Pharmaceuticals Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 4 weeks ago

Vanda Pharmaceuticals Proxy statement: Proxy filing


Vanda Pharmaceuticals Slides: Corporate presentation

Mar 6, 2026, 6:00 AM EST - 2 months ago

Vanda Pharmaceuticals Slides: Corporate presentation


Vanda Pharmaceuticals initiated with a Buy at Truist

2026-03-05T11:11:50.000Z - 2 months ago

Vanda Pharmaceuticals initiated with a Buy at Truist


Vanda announces FDA accepted BLA for imsidolimab

2026-02-25T12:23:26.000Z - 3 months ago

Vanda announces FDA accepted BLA for imsidolimab


US FDA approves Vanda's psychiatric drug

Feb 20, 2026, 6:03 PM EST - 3 months ago

US FDA approves Vanda's psychiatric drug


Vanda Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 11, 2026, 4:30 PM EST - 3 months ago

Vanda Pharmaceuticals Earnings Call Transcript: Q4 2025


Vanda Pharmaceuticals Annual report: Q4 2025

Feb 11, 2026, 4:30 PM EST - 3 months ago

Vanda Pharmaceuticals Annual report: Q4 2025


Vanda Pharmaceuticals Earnings release: Q4 2025

Feb 11, 2026, 4:30 PM EST - 3 months ago

Vanda Pharmaceuticals Earnings release: Q4 2025


Vanda Pharmaceuticals Slides: Corporate presentation

Jan 15, 2026, 7:00 AM EST - 4 months ago

Vanda Pharmaceuticals Slides: Corporate presentation


Vanda and Exante Data Combine in Strategic Merger

Jan 8, 2026, 9:31 AM EST - 4 months ago

Vanda and Exante Data Combine in Strategic Merger


US FDA approves Vanda Pharmaceuticals' motion sickness drug

Dec 30, 2025, 6:30 PM EST - 5 months ago

US FDA approves Vanda Pharmaceuticals' motion sickness drug


Vanda Pharmaceuticals Slides: Corporate Presentation

Nov 9, 2025, 6:00 PM EST - 7 months ago

Vanda Pharmaceuticals Slides: Corporate Presentation


Vanda Pharmaceuticals Earnings Call Transcript: Q3 2025

Oct 29, 2025, 4:30 PM EDT - 7 months ago

Vanda Pharmaceuticals Earnings Call Transcript: Q3 2025


Vanda Pharmaceuticals Quarterly report: Q3 2025

Oct 29, 2025, 4:30 PM EDT - 7 months ago

Vanda Pharmaceuticals Quarterly report: Q3 2025


Vanda Pharmaceuticals Earnings release: Q3 2025

Oct 29, 2025, 4:30 PM EDT - 7 months ago

Vanda Pharmaceuticals Earnings release: Q3 2025


Vanda Pharmaceuticals Earnings Call Transcript: Q2 2025

Jul 31, 2025, 8:00 AM EDT - 10 months ago

Vanda Pharmaceuticals Earnings Call Transcript: Q2 2025


Vanda Pharmaceuticals Quarterly report: Q2 2025

Jul 31, 2025, 8:00 AM EDT - 10 months ago

Vanda Pharmaceuticals Quarterly report: Q2 2025


Vanda Pharmaceuticals Earnings release: Q2 2025

Jul 31, 2025, 8:00 AM EDT - 10 months ago

Vanda Pharmaceuticals Earnings release: Q2 2025


Vanda Pharmaceuticals Proxy statement: Proxy Filing

May 27, 2025, 8:00 AM EDT - 1 year ago

Vanda Pharmaceuticals Proxy statement: Proxy Filing


Vanda Pharmaceuticals Earnings Call Transcript: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Vanda Pharmaceuticals Earnings Call Transcript: Q1 2025


Vanda Pharmaceuticals Quarterly report: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Vanda Pharmaceuticals Quarterly report: Q1 2025


Vanda Pharmaceuticals Earnings release: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Vanda Pharmaceuticals Earnings release: Q1 2025


Vanda Pharmaceuticals Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Vanda Pharmaceuticals Proxy statement: Proxy Filing


Vanda Pharmaceuticals Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Vanda Pharmaceuticals Proxy statement: Proxy Filing


Wolfietrader
Wolfietrader May. 25 at 8:08 PM
$VNDA I just saw their silly cartoon commercial during the Paris Open. What a joke
0 · Reply
RayaK16
RayaK16 May. 23 at 11:34 PM
0 · Reply
elmono
elmono May. 23 at 7:30 AM
$VNDA their biggest mistake is that they are overspending. Cut cost by 50% and this is going somewhere….otherwise next offering in Q4
0 · Reply
BullMaven
BullMaven May. 22 at 3:12 PM
$VNDA adding 500
0 · Reply
TomMac64
TomMac64 May. 22 at 1:56 PM
$VNDA My favorite Company , stock , play , whatever ; this is gonna be $10 …..
0 · Reply
Cmhatwell
Cmhatwell May. 22 at 12:52 PM
$VNDA merger monday, oh wait a minute.
1 · Reply
Investor203
Investor203 May. 22 at 11:49 AM
$AKTX any hope for $VNDA?
2 · Reply
jacckkmm
jacckkmm May. 21 at 11:04 AM
$VNDA is a player here!The Charcot–Marie–Tooth disease market is poised for steady growth, driven by increasing disease awareness and improved diagnostic capabilities. Advancements in genetic testing are enabling earlier and more accurate diagnosis, expanding the identifiable patient pool. Additionally, the expected launch of emerging therapies such as IFB-088 (InFlectis BioSciences), Govorestat (Applied Therapeutics), Ignaseclant (NMD670) (NMD Pharma), ABS-0871 (Actio Biosciences), VCA-894A (Vanda Pharmaceuticals), EDK060 (Novartis), AGT-100216 (Augustine Therapeutics), and others will further boost the market growth forward.
1 · Reply
veryboredXYZ
veryboredXYZ May. 21 at 1:36 AM
$VNDA time to turn this around. Enough bleeding
0 · Reply
BioRich
BioRich May. 20 at 11:14 PM
$SLS The more y'all play childish games, the more I feel it's easier to respond broadly than specifically. Here's another one of your distraught RH's. @Jesse1011 THOUSANDS of posts, and you hand select these? Interesting. $GUTS doubled after I picked it. $SLS 8x'd after i picked it. $CAPR multipled and the list goes on. $GPCR, you point out that i asked if something leaked. That's it. And someone explained the upward movement. It's often included in BO discussions, which I still believe it gets. $VNDA is great and have made lots on them. Added for earnings and the did what appeared to be an unnecessary offering. Still massively green on it and expect a natural rebound. ANVS... you saw what it did after my post, right? You know, the respinse that was exsctly like i suggested. So keep highlighting my excellence. And it'll be beautiful when you look at my posts exposing $SLS in the future. Because lets be real, that's the only reason you're acting out.
9 · Reply
BioRich
BioRich May. 20 at 6:49 AM
$SABS (#11) 12) $WVE 13) $BBAI 14) $VNDA 15) $OCUL (Sorry, using this is a placeholder to see how these track over time from today. Posting late so as to not clog the boards or appear as spam. These are my actual rankings)
1 · Reply
SuperGreenToday
SuperGreenToday May. 20 at 5:21 AM
$VNDA Share Price: $5.99 Contract Selected: Dec 18, 2026 $5 Calls Buy Zone: $1.99 – $2.46 Target Zone: $3.21 – $3.93 Potential Upside: 53% ROI Time to Expiration: 212 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
cb28
cb28 May. 19 at 8:10 PM
$VNDA sucks to see I'm in SLS meantime will jump back in once thats settled.
0 · Reply
Its_Only_Money_369
Its_Only_Money_369 May. 19 at 7:00 PM
$VNDA 50MA just crossed the 200 on the weekly chart
1 · Reply
MattyMoMo
MattyMoMo May. 19 at 6:51 PM
$VNDA In the past 3 months... we've gone from $6 to $10 and back to $6! 😪
0 · Reply
Massimo21
Massimo21 May. 19 at 6:32 PM
$VNDA In today's presentation the HCW moderator said, Tradipitant has an interesting history. It was developed by Lilly. Make of it whatever you want.
1 · Reply
BullMaven
BullMaven May. 19 at 4:37 PM
$VNDA adding a bit more 500
0 · Reply
TradPoof
TradPoof May. 19 at 10:45 AM
$VNDA Waiting getting $6 for DCA. Hold patiently. Commercial launching soon. BYSANTI™'s unique in-class receptor binding profile, featuring strong alpha-adrenergic binding in excess of dopamine and serotonin receptor binding, makes it suitable for further investigation in conditions that include symptoms of hostility, agitation, and hyperarousal. Vanda anticipates commercial availability of BYSANTI™ in Q3 of 2026. BYSANTI™ marketing exclusivity is expected to be protected by regulatory data exclusivity and issued US patents, with the latest expiring in 2044, providing a robust foundation for long-term innovation and patient benefit. 👍👍👍
1 · Reply
TomMac64
TomMac64 May. 19 at 10:41 AM
$VNDA You couldn’t be more wrong this is last gap !
1 · Reply
Unicorn2020
Unicorn2020 May. 18 at 11:13 PM
$VNDA There is one more gap @ $4.50
1 · Reply
BullMaven
BullMaven May. 18 at 7:33 PM
$VNDA added 1500 at 6.04
0 · Reply
PB09
PB09 May. 18 at 6:50 PM
$VNDA Added 15k shares today, will be my 2nd rinse & repeat
0 · Reply